No State Law Remedies for Failure to Comply with BPCIA Notice


On remand from the Supreme Court of the United States, the US Court of Appeals for the Federal Circuit held that under the Biologics Price Competition and Innovation Act of 2009 , state law claims and remedies are not available in biosimilar patent litigation. Amgen Inc. v.



from Biotech News